Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the use of digital tools in dentistry to improve the detection of dental conditions in adults. It compares the standard real-life examination by practitioners, which combines clinical and radiographic assessments, with examinations based on imaging results from digital devices. The study follows up on previous research that provided recent insights into adult patients oral health and care needs. The study involves digital imaging technologies such as intraoral scanners optical impression cameras, panoramic radiography orthopantomogram, and Cone Beam Computed Tomography CBCT. These tools provide 3D images and detailed views of dental structures, potentially offering more systematic and rapid clinical data collection. Radiographs are only performed when medically justified, and there are no deviations from standard care. Participants attend a single study visit where data is collected through clinical examination and imaging results. Researchers will assess various dental conditions, including the number of decayed, missing, or filled teeth, the extent and location of carious and wear lesions, dental restorations, periodontal involvement, and endodontic status. The study focuses on improving the quality and completeness of diagnostic information to support better treatment planning.
Actively Recruiting
Large-cell neuroendocrine carcinomas LCNECs of the lung are rare, aggressive tumors with poor prognosis and limited treatment options. Researchers are evaluating the combination of durvalumab with etoposide and platinum chemotherapy as a first-line treatment to improve the progression-free rate at 12 months in patients with advanced LCNEC confirmed by expert pathologist review. This phase II, multicenter, open-label study aims to assess the efficacy and safety of this combination compared to historical data. Participants will receive durvalumab combined with etoposide and either cisplatin or carboplatin. Treatment includes an induction phase with cycles every three weeks for 12 weeks four cycles, followed by a maintenance phase with durvalumab every four weeks for up to 24 months. This prospective study uses an external control arm for comparison and focuses on first-line treatment of advanced LCNEC. During the study, patients will be closely monitored through scheduled visits and assessments, including radiological evaluations to measure disease progression. Researchers will track the progression-free rate at 12 months as the primary outcome and also evaluate objective response rates, disease control rates, overall survival, and safety profiles over a period of up to 63 months. Participants will be followed for adverse events and treatment-emergent effects for up to 27 months and 90 days post-treatment, ensuring comprehensive safety and efficacy evaluation.
Actively Recruiting
Researchers are exploring the potential benefits of a respiratory training program called cardiac coherence in people who have acute stress disorder after experiencing a traumatic event. This pilot study aims to see if this method can help prevent chronic post-traumatic stress disorder from developing after three months. The study also seeks to understand how feasible and acceptable the program is for patients. Participants will learn how to practice cardiac coherence with guidance from a trained practitioner during their first visit. They will receive a smartphone app to guide their breathing and a diary to track their adherence. The training involves performing six respiratory cycles per minute, with specific inhale and exhale durations, for five minutes, three times a day at home over three months. During the study, patients will be monitored through questionnaires and heart rate variability measurements at the start and after three months. Compliance with the breathing exercises will be tracked monthly. Researchers will assess the proportion of patients who do not develop post-traumatic stress disorder by month three, as well as any complications related to the disorder. The total participation lasts at least three months, including ongoing support and evaluation.
Actively Recruiting
People with mental disorders tend to smoke more than the general population, which contributes to a significant reduction in their life expectancy, mainly due to cardiovascular and respiratory diseases like bronchial cancers. Smoking cessation efforts targeting this group, especially in psychiatric care, are often insufficient. This study evaluates a new intervention called Tabapsy, designed in collaboration with mental health users, professionals, and general practitioners, aimed at helping adults receiving outpatient psychiatric care reduce or quit smoking. The Tabapsy intervention includes a campaign promoting smoking cessation within psychiatric medical psychological centers CMPs and a structured program to support quitting. This program involves a general information meeting to encourage motivation, an assessment workshop to personalize cessation plans based on nicotine dependence, five thematic workshops addressing treatments, emotional management, weight gain, physical activities, and manual occupations, plus peer support groups to foster mutual aid. A facilitator leads these workshops, and a website complements the resources provided. The trial compares this intervention against usual smoking cessation practices in randomized psychiatric sectors. Participants who regularly smoke and agree to join will complete questionnaires at the start, 3 months, and 6 months, assessing tobacco use, dependence, motivation, well-being, knowledge, and satisfaction. The study will measure short-term smoking cessation at 3 months as the primary outcome, along with various secondary outcomes including motivation, quit attempts, mental and physical well-being, cost-effectiveness, and implementation success. The trial plans to include 6,250 participants over 12 months and will combine quantitative and qualitative evaluations.
Actively Recruiting
Researchers are evaluating the effect of music therapy combined with standard care compared to standard care alone on psychological pain in patients with suicidal thoughts or recent suicide attempts. The study aims to understand if adding music therapy can help reduce psychological distress in this vulnerable population. This is a controlled, randomized trial sponsored by the Centre Hospitalier Universitaire de la Runion. Participants in the music therapy group will receive four 30-minute sessions of receptive music therapy within 48 hours. The standard care includes medical and paramedical interviews lasting 20 to 30 minutes, prescription of anxiolytic or hypnotic drugs, and hospitalization with regular psychological evaluations. Patients are randomized to either receive music therapy plus usual care or usual care alone. During the study, psychological pain will be measured before and after each music therapy session using an analogical visual scale. Participants are hospitalized for 48 to 60 hours with ongoing evaluations of their psychological status. The main outcome is the change in psychological pain 48 hours after inclusion. The study continues until November 2027, with careful monitoring throughout hospitalization and treatment.
Actively Recruiting
Researchers are evaluating a simple and rapid screening tool designed to detect decompensated heart failure in patients aged 55 and older who are hospitalized in cardiology units on Runion Island. This preliminary, cross-sectional study aims to determine whether this tool can accurately identify patients with a high probability of this condition when compared to the gold standard cardiology examination. The study is conducted at two hospital centers and does not alter the participants usual care. The study involves two phases first, the development of the new e-DELPHI consensus-based screening tool, and second, the administration of the DspistIC-Run early detection questionnaire alongside the standard cardiology examination RIPH3. The questionnaire is used as a diagnostic test to assess heart failure without impacting the patients standard treatment. Participants will be assessed during their hospital stay with the screening questionnaire and cardiology evaluations. Researchers will collect sociodemographic, clinical, and lifestyle information to describe the study population and compare them with other patient groups. The main outcome is to estimate how well the screening tool can discriminate decompensated heart failure from enrollment until six months. The study is expected to be completed by February 2027.